master's thesis
Hepatitis B virus mutants influence on chronic HBV infection therapy

Ivana Fileš (2015)
Sveučilište u Zagrebu
Farmaceutsko-biokemijski fakultet
Zavod za biokemiju i molekularnu biologiju
Metadata
TitleUloga mutanata virusa hepatitisa B u liječenju kronične HBV infekcije
AuthorIvana Fileš
Mentor(s)Sandra Šupraha Goreta (thesis advisor)
Abstract
Hepatitis B je upala jetre koja nastaje infekcijom virusom hepatitisa B (HBV). Najčešće se javlja kao akutni hepatits, no kod malog postotka inficiranih osoba prelazi u kronični oblik koji predstavlja visok rizik za razvoj ciroze jetre ili hepatocelularnog karcinoma. Procjenjuje se da je trenutan broj kronično zaraženih osoba u cijelom svijetu oko 240 milijuna, što ga čini značajnim faktorom morbiditeta i mortaliteta. Virus je vrlo infektivan, a prenosi se kontaktom sa zaraženim tjelesnim tekućinama. Replikacija virusa uključuje reverznu transkripciju uz virusnu DNA polimerazu koja nema ispravljačku sposobnost. To rezultira pojavom mutantnih virusa koji se mogu izdvojiti djelovanjem imunološkog sustava ili pod utjecajem antivirotika. Brojna su istraživanjaje pokazala da genetička varijabilnost virusa utječe na brzinu progresije bolesti, pouzdanost dijagnostičkih metoda, uspjeh antivirusne terapije i imunizacije. Mutacije u površinskom antigenu HBsAg mogu dovesti do neuspješne imunizacije cijepljenjem („escape“ mutanti) te neuspješne detekcije dijagnostičkim metodama. Nemogućnost detekcije predstavlja problem jer takve osobe mogu postati donori krvi i tako širiti zarazu. Također, mutacije u YMDD motivu virusne DNA polimeraze imaju važnu ulogu u razvoju rezistencije na nukleoz(t)idne analoge. Praćenje HBV mutacija važno je u svrhu bolje prevencije, dijagnoze te stvaranja efikasne antivirusne terapije.
Keywordshepatitis B virus chronic hepatatis B HBV mutations drug resistance vaccine escape mutants
Parallel title (English)Hepatitis B virus mutants influence on chronic HBV infection therapy
Committee MembersSandra Šupraha Goreta
Olga Gornik
Miranda Sertić
GranterSveučilište u Zagrebu
Farmaceutsko-biokemijski fakultet
Lower level organizational unitsZavod za biokemiju i molekularnu biologiju
PlaceZagreb
StateCroatia
Scientific field, discipline, subdisciplineBIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Study programme typeuniversity
Study levelintegrated undergraduate and graduate
Study programmePharmacy
Academic title abbreviationmag. pharm.
Genremaster's thesis
Language Croatian
Defense date2015-09-25
Parallel abstract (English)
Hepatitis B is a liver inflammation caused by hepatitis B virus (HBV) infection. Usually it occurs as acute hepatitis, but in some cases virus remains in patient, causing a chronic infection. Consequently, it can lead to development of cirrhosis and hepatocellular carcinoma. Worldwide, there are an estimated 240 million chronically infected persons. Therefore, chronic HBV infection is a major public health issue. Hepatitis B virus is very infectious and it spreads through contact with infected body fluids. Virus replication includes reverse transcription using a viral DNA polymerase lacking proof-reading ability. This results in the emergence of mutant viruses that can be selected out by host immunity or antiviral drugs. Numerous research studies have shown that the speed of disease progression, reliability of diagnostic methods and the success of antiviral therapy and immunization are all influenced by genetic variability of the virus. Mutations in hepatitis B surface antigen (HBsAg) may lead to evasion of vaccine-induced immunity („vaccine escape“ mutants) and loss of HBV detection by diagnostic assays. The inability to detect HBV means that these individuals may become blood donors and continue HBV transmission. Also, mutations in YMDD motif of viral DNA polimerase are associated with resistance to nucleos(t)ide analogues. Monitoring of HBV mutations contributes to improvement of prevention, diagnosis and creating more efficient antiviral therapy.
Parallel keywords (Croatian)hepatitis B virus kronični hepatitis B HBV mutacije rezistencija na lijekove vaccine escape mutanti
Resource typetext
Access conditionOpen access
Terms of usehttp://rightsstatements.org/vocab/InC/1.0/
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:163:902946
CommitterPetra Gašparac